CLEVELAND, OHIO — Convelo Therapeutics, Inc., a biotechnology company with a mission to discover a new class of medicines that regenerate the protective myelin coating around nerve cells, has entered into an exclusive worldwide collaboration with Genentech, a member of the Roche Group, to accelerate discovery and development of novel remyelinating medicines for patients with neurological disorders such as multiple sclerosis (MS).
Read MoreCLEVELAND, OHIO — Convelo Therapeutics, Inc. announced today that it has launched from stealth mode with a mission to discover and develop a new class of medicines that regenerate the protective myelin coating around nerve cells that is lost in a wide array of neurological diseases, including multiple sclerosis (MS). Seminal scientific discoveries made in the laboratories of Drs. Paul Tesar and Drew Adams at Case Western Reserve University School of Medicine provide the foundation of Convelo’s discovery platform. Their most recent work, published online today in the journals Nature and Nature Methods, identified a central molecular pathway for stimulating the regeneration of new myelinating cells in the central nervous system.
Read More